Cargando...
Emerging options for the treatment of melanoma – focus on ipilimumab
Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody. It has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for use in advanced melanoma following clear evidence of survival benefit in randomized...
Gardado en:
| Publicado en: | Immunotargets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918235/ https://ncbi.nlm.nih.gov/pubmed/27482517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S43522 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|